What are the dosing guidelines, contraindications, monitoring parameters, and common adverse effects of Qelbree (viloxazine) for ADHD?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Qelbree (Viloxazine Extended-Release) for ADHD

Qelbree is a non-stimulant ADHD medication that should be started at 100 mg daily in children (6-11 years), 200 mg daily in adolescents (12-17 years), and 200 mg daily in adults, with upward titration to optimal doses of 200-400 mg/day in children, 400-600 mg/day in adolescents, and 400-600 mg/day in adults based on response and tolerability. 1

Dosing Guidelines

Pediatric Dosing (Ages 6-17)

  • Children 6-11 years:

    • Start: 100 mg once daily
    • Target range: 200-400 mg/day
    • Maximum: 400 mg/day
  • Adolescents 12-17 years:

    • Start: 200 mg once daily
    • Target range: 400-600 mg/day
    • Maximum: 600 mg/day

Adult Dosing (Ages 18-65)

  • Start: 200 mg once daily
  • Target range: 400-600 mg/day (mean effective dose ~504 mg/day)
  • Maximum: 600 mg/day 1, 2

Titration strategy: Recent dose-effect meta-analysis data shows that efficacy plateaus around 400 mg/day in children and adolescents, with no compelling evidence for routine use above FDA-licensed maxima 3. The optimal therapeutic window appears to be 200-400 mg (or 6-8 mg/kg) in pediatric patients 4.

Contraindications

Absolute contraindications:

  • Concomitant use with MAOIs or within 14 days of MAOI discontinuation (risk of hypertensive crisis)
  • Concomitant use with sensitive CYP1A2 substrates or those with narrow therapeutic range (e.g., theophylline, tizanidine) 1

Screen before initiating:

  • Personal or family history of bipolar disorder, suicide, or depression (risk of activation of mania/hypomania and suicidal ideation) 1
  • Active substance use disorder in adolescents (requires subspecialist consultation) 5

Monitoring Parameters

Baseline Assessment

  • Blood pressure and heart rate
  • Weight and height (calculate BMI percentile in pediatrics)
  • Psychiatric history screening for bipolar disorder and suicidality
  • Substance use screening in adolescents 1

Ongoing Monitoring

  • Cardiovascular: Blood pressure and heart rate at each visit (Qelbree causes modest increases)
  • Weight: Monitor regularly; expect minimal weight gain (0.2 kg) in younger children and slight weight loss (-0.2 kg) in adolescents over 6-8 weeks 1
  • Suicidality: Use Columbia Suicide Severity Rating Scale (C-SSRS) at regular intervals 6
  • Symptom response: ADHD Rating Scale assessments; therapeutic effects typically emerge within 2-3 weeks and plateau around weeks 4-6 4, 2

Drug Interaction Monitoring

  • CYP1A2 substrates: Viloxazine is a strong CYP1A2 inhibitor; avoid coadministration or reduce doses of CYP1A2 substrates
  • CYP2D6 and CYP3A4 substrates: Viloxazine is a weak inhibitor; monitor for adverse effects and adjust substrate doses as needed 1

Common Adverse Effects

Pediatric Patients (6-17 years)

Most common (≥5% and twice placebo rate):

  • Somnolence: 16% (vs 4% placebo) - dose-related, highest at 400 mg
  • Decreased appetite: 7% (vs 0.4% placebo)
  • Headache: 11%
  • Fatigue: 6% (vs 2% placebo)
  • Nausea: 5% (vs 3% placebo)
  • Vomiting: 4% (vs 2% placebo)
  • Insomnia: 4% (vs 1% placebo)
  • Irritability: 3% (vs 1% placebo) 1

Adult Patients

Most common (≥5% and twice placebo rate):

  • Insomnia: 23% (vs 7% placebo)
  • Headache: 17% (vs 7% placebo)
  • Fatigue: 12% (vs 3% placebo)
  • Nausea: 12% (vs 3% placebo)
  • Decreased appetite: 10% (vs 3% placebo)
  • Dry mouth: 10% (vs 2% placebo)
  • Somnolence: 6% (vs 2% placebo)
  • Constipation: 6% (vs 1% placebo) 1

Discontinuation rates: 3% in pediatrics and 9% in adults due to adverse events, with most events being mild to moderate 1, 6

Clinical Pearls and Pitfalls

Timing of effects: Symptom improvement begins within 2-3 weeks, with maximal benefit by weeks 4-6. The 100 mg dose shows more rapid decline in efficacy over time compared to 200-400 mg doses 4.

Somnolence management: This is the most common pediatric adverse effect (16%). Patients should not operate vehicles or machinery until they know how Qelbree affects them 1. Consider dosing adjustments or timing changes if problematic.

Avoid subtherapeutic dosing: The 2026 dose-effect meta-analysis emphasizes that suboptimal dosing is common in clinical practice and reduces treatment adherence. Clinicians should titrate upward from minimal doses when symptoms remain insufficiently controlled 3.

Adolescent driving safety: Given ADHD-related crash risks, ensure medication coverage during driving hours. Consider timing of once-daily dosing or adding short-acting coverage if needed 5.

Combination with stimulants: Real-world data suggests viloxazine ER may allow reduction in stimulant dosages and overall psychiatric medication burden when used concomitantly 7.

Long-term safety: Data extending to 72 months in pediatrics shows sustained efficacy with no new safety signals emerging over time 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.